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computed tomography scan had no Cloquet node identified intraoperatively but had positive
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tients. Three patients developed distant metastases and two patients were disease free to
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biopsy can potentially diagnose occult metastases in otherwise nonenlarged nodes.
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Management of inguinal nodal metastases 411. Introduction
Extramammary Paget disease (EMPD) is a distinct form of
rare malignant skin neoplasm first described by Radcliffe
Crocker in 1889.1 EMPD is known to affect primarily post-
menopausal Caucasian females with a female-to-male ratio
of 4:1.2e4 The lesions commonly develop in the vulva,
penis, scrotum, perineum, perianal area, umbilicus, or ax-
illa.5 Primary EMPD arises from underlying neoplastic
transformation of basal epithelial cells of the epidermis or
the epithelial cells in the intraepidermal portion of sweat
glands. By contrast, the secondary form of EMPD is caused
by intraepidermal spreading of neoplastic cells typically
from an underlying adenocarcinoma.6,7
EMPD lesions are generally confined to the epidermis.
However, as the disease progresses, EMPD is known to
invade the dermis and metastasize to regional lymph nodes
or distant organs.8 Wide excision is currently the treatment
of choice for early EMPD, whereas lymph node dissection is
only performed when nodal metastases are present.
Compared with patients with carcinoma in situ, patients
with EMPD invading beyond the dermis or subcutaneous
tissues or regional lymph node metastasis appear to have a
much worse prognosis.9,10 The 5-year survival rate of pa-
tients with lymph node metastasis is extremely poor. In a
retrospective analysis of 34 patients with genital EMPD in
the study by Tsutsumida et al,11, no patients with nodal
metastases survived >50 months. By contrast, the remain-
ing patients without lymph node metastases had a cumu-
lative survival of >5 years. In the study by Ito et al,12 the 5-
year survival rate of patients with genital EMPD and nodal
metastases was 20%, compared to 87.4% in patients without
nodal metastases.
The published series of EMPD described lymphadenec-
tomy for the treatment of inguinal nodal metastases but did
not describe the more extensive combined groin dissection
(CGD) more commonly performed for inguinal and pelvic
nodal metastases in malignant melanoma.11e13 In a study
reported by Karouski et al,14 favorable 10-year survival
rates of 25% have been observed in melanoma patients with
nodal disease who underwent CGD.
In this study, we describe our experience in the man-
agement of five male patients with advanced primary EMPD
of the scrotum and palpable inguinal nodal metastases from
a total of 14 patients with EMPD treated at the Singapore
National Cancer Centre, Singapore between January 2002
and January 2012. In addition, we performed a literature
review of published studies describing the management of
nodal metastases in individuals with genitalia EMPD.
2. Materials and methods
The SingHealth Institute Ethics Board-approved retrospec-
tive analysis examines a prospectively maintained database
of 14 EMPD patients treated at the Singapore National
Cancer Centre, a tertiary referral center, between the 11-
year period of January 2002 to January 2012. Five patients
with inguinal nodal involvement who underwent CGD were
reviewed.
The medical records of these patients were obtained
from a prospectively maintained computerized clinicaldatabase (Sunrise Clinical Manager version 5.8, Eclipsys
Corporation, Atlanta, Georgia). Surgical findings and surgi-
cal procedures were also obtained from another prospec-
tively maintained computerized operative database (OTM
10, IBM, Armonk, New York). These patients had been
evaluated by routine history and physical examination,
chest radiography, and blood profiles at the time of pre-
sentation. Imaging studies using computed tomography (CT)
or magnetic resonance imaging (MRI) were also performed
to evaluate locoregional disease. All the biopsy results and
preoperative imaging scans were reviewed prior to surgical
treatment by a multidisciplinary tumor board to assess the
extent of local disease and lymph node involvement. All of
the patients subsequently underwent surgery within 1
month after diagnosis.
All patients underwent wide resection of the lesion until
the frozen sections of the margins were negative. Superfi-
cial groin dissection (SGD) was defined as the complete
dissection of lymph nodes from the inguinofemoral content
to the apex of the femoral triangle. CGD further included
dissection of the external iliac nodes up to at least the
bifurcation of the common iliac artery and dissection of the
obturator nodes. Consideration was made for CGD if
the preoperative CT/MRI studies showed significantly
enlarged lymph nodes along the iliac vessels or when the
frozen section of the Cloquet node was positive for disease.
Lymph nodes were considered significantly enlarged if they
were >1 cm on CT/MRI. The Cloquet node was defined as
the lymphatic tissue medial to the femoral vein at the su-
perior aspect of the femoral canal and is thought to repre-
sent the leading lymph node into the pelvis from the inguinal
basin. Reconstruction was performed primarily with a
sartorius flap to cover the femoral vessels. Closed suction
drains were placed in the area of the groin dissection.
The resected primary lesion and dissected lymph nodes
were sent for histological examination. The epidermis
showed tumor cells with large atypical nuclei and abundant
cytoplasm, arranged singly and in small groups. Histo-
chemical stains and immunohistochemical stains had been
used, when necessary, to confirm the glandular nature of
these cells and to rule out the possibility of a secondary
EMPD. The resection margins, depth of invasion, and pres-
ence of nodal metastasis were assessed. The histological
slides were reviewed specifically for the presence of inva-
sion into the dermis, subcutaneous tissue, smooth muscle
of the scrotum (dartos muscle), regional skeletal muscles,
or blood vessels. The number and the level of inguinal and
iliac node involvement by metastasis, with or without the
presence of extranodal spread, were also recorded.
Patients were then followed up every 3e6 months after
surgery. Surveillance biopsies and imaging studies were not
routinely performed in asymptomatic patients. Clinical in-
vestigations were performed according to the patient’s
symptoms at follow-up.3. Results
Scrotal primary EMPDs were diagnosed in five Asian males,
mean age 62.5 years (range: 43e77 years). All patients
underwent scrotal incision or punch biopsies, which sug-
gested EMPD of the scrotum. Fine-needle aspiration
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42 Y.X. Koh et al.cytology of the inguinal lymph nodes was performed in
three patients, and only one had positive results. Imaging
studies suggested involvement of the pelvic nodes in three
patients; histology confirmed involvement in two of them.
Two patients developed wound infection and lymphedema
after CGD (Table 1).
All patients had invasion to the dermis and one patient
had invasion to the dartos muscle; another had tumor
invading into the skeletal muscle and femoral vein. All
radial skin margins were negative; the closest margin was
4 mm. Of the four patients who had positive Cloquet node
involvement on frozen section and formal histology, one
had pelvic nodal disease. In another patient with pelvic
nodal metastases seen on CT scan, the Cloquet node was
not identified intraoperatively but positive pelvic nodal
metastases were present (Table 2).
The mean disease-free survival (DFS) and the overall
survival (OS) were 28.6 months (range: 2e60 months) and
33.4 months (range: 2e60 months), respectively, for all
patients. Three patients developed distant metastases and
two patients were disease free.T
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.4. Discussion
Geital EMPD is rare and most studies have limited numbers
(n < 50) in most published series. From our review, there
were 205 cases of genital EMPD reported from six case series
worldwide, of which 47.3% (n Z 97) of them had invasive
disease. Genital EMPD with inguinal nodal metastases ac-
counts for 35.1% of all invasive genital EMPD and 16.5% of all
genital EMPD cases. Of those with invasive EMPD, only 37.1%
(n Z 36) underwent SGD and 34 of 36 had evidence of
inguinal nodal metastases on dissection.11e13,15e18
There is currently no universally accepted approach to
the management of inguinal and pelvic nodal disease in
these EMPD patients. The available evidence in the man-
agement of this disease is presented in Table 3.
Achieving adequate margins for the primary skin lesions
is an important factor in reducing the risk of recurrent
disease. It was suggested that the critical factor in the
management of the primary skin lesions was the vertical
invasion at the local region, and that a wide excision margin
of 2e5 cm for the primary genital lesion was recom-
mended.11,19 In our series, the radial and vertical margins
were aggressively pursued; consequently, no patient
developed locoregional recurrence.
The depth of the primary lesion of the EMPD has also
been thought to influence the development of nodal me-
tastases and overall survival; several studies have reported
that all patients with only intraepidermal disease did not
develop nodal metastases. Furthermore, the survival of
these patients was significantly better than those with
invasive disease, median survival of 55 months versus 14.5
months.13,17
Tsutsumida et al11 proposed an algorithm for lymph node
dissection according to the depth of invasion of the primary
lesion. When invasion to the dermis or subcutaneous tissue
is found, elective lymph node dissection is strongly rec-
ommended even in the absence of clinically palpable
inguinal nodes. In this study, survival was adversely
affected by the depth of tumor invasion. When the tumor
T
a
b
le
2
P
a
th
o
lo
gi
ca
l
fa
ct
o
rs
in
re
la
ti
o
n
to
d
is
e
a
se
-f
re
e
su
rv
iv
a
l
a
n
d
o
ve
ra
ll
su
rv
iv
a
l.
P
a
ti
e
n
t
n
o
.
R
a
d
ia
l
m
a
rg
in
s
o
f
sc
ro
ta
l
le
si
o
n
(m
m
)
D
e
e
p
m
a
rg
in
s
o
f
sc
ro
ta
l
le
si
o
n
D
e
p
th
o
f
p
ri
m
a
ry
E
M
P
D
in
va
si
o
n
N
o
.
o
f
ly
m
p
h
n
o
d
e
s
in
vo
lv
e
d
P
a
th
o
lo
gi
ca
l
st
a
tu
s
o
f
p
e
lv
ic
n
o
d
e
La
rg
e
st
ly
m
p
h
n
o
d
e
si
ze
(m
m
)
E
xt
ra
n
o
d
a
l
sp
re
a
d
D
is
e
a
se
-f
re
e
su
rv
iv
a
l
(m
o
)
O
ve
ra
ll
su
rv
iv
a
l
(m
o
)
1
10
N
e
ga
ti
ve
D
e
e
p
d
e
rm
is
12
/1
3
N
e
ga
ti
ve
20
N
o
46
(l
u
n
g
m
e
ta
st
a
se
s)
48
2
4
P
o
si
ti
ve
Sk
e
le
ta
l
m
u
sc
le
,
fe
m
o
ra
l
ve
in
42
/4
2
P
o
si
ti
ve
35
Y
e
s
2
(b
o
n
e
m
e
ta
st
a
se
s)
2
3
10
N
e
ga
ti
ve
D
a
rt
o
s
m
u
sc
le
8/
9
N
e
ga
ti
ve
35
Y
e
s
6
6
4
20
N
e
ga
ti
ve
D
e
e
p
d
e
rm
is
2/
13
N
e
ga
ti
ve
10
N
o
60
60
5
17
N
e
ga
ti
ve
D
e
e
p
d
e
rm
is
8/
34
P
o
si
ti
ve
35
N
o
29
(c
e
rv
ic
a
l
n
o
d
e
a
n
d
p
e
ri
to
n
e
a
l
m
e
ta
st
a
se
s)
51
E
M
P
D
Z
e
xt
ra
m
am
m
a
ry
P
a
ge
t
d
is
e
a
se
.
Management of inguinal nodal metastases 43extended into the dermis, 50% of the patients (3 of 6) were
found to have nodal metastases; the median survival was 54
months with no 5-year survivors. When the tumor extended
deeper to the subcutaneous tissue, all six patients had
lymph node metastasis; the median survival was 24 months
and likewise there were no 5-year survivors.11 Similarly, Ito
et al12 showed an inferior 5-year survival rate of D patients
with EMPD and positive nodal involvement versus negative
nodal involvement (20% vs. 87.4%).12 In another study by
Yoshino et al,20 the number of nodes involved was a crucial
determinant of survival. In patients with more than a single
positive node, the 5-year survival rate was only 13.5%
compared to 100% in patients with only single node
involvement.
This poor survival was not observed in our case series.
There were three patients with dermal invasion and mul-
tiple involved nodes who underwent combined groin
dissection and enjoyed relatively long survival (4e5 years;
Table 2). Furthermore, all the patients in our series did not
develop recurrent locoregional disease. At our center, CGD
is guided by the intraoperative frozen section results of the
Cloquet node and imaging investigations are also taken into
consideration. The Cloquet node has been identified to
reflect the status of the pelvic nodes in the treatment of
melanomas with groin nodal metastases, the positive pre-
dictive value of a positive Cloquet node was >67%.21e23
Although the positive predictive value of the Cloquet
node for EMPD in our series was much lower, the removal of
the involved Cloquet node was important in ensuring com-
plete lymphadenectomy.
According to our results, muscle and vascular invasion
were very poor prognostic indicators. In the patient with
these factors, metastatic disease developed 2 months after
the surgery; the patient died. This indicates that, although
effective in the management of nodal metastases, CGD
should not be performed on patients with EMPD with a poor
prognosis. In such cases, palliative surgery or radiation
therapy would be a more appropriate alternative.
The study by Ito et al12 in the prognostication of EMPD does
not analyze the patients according to the number and level
(i.e., inguinal vs. pelvic) of nodal disease. Becausemost of the
studies describing SGD did not progress to CGD, there are no
available data on this important aspect.11,13,15 The only other
study that described CGD was that by Hegarty et al,17 who
included in their series CGD for two patients who had pelvic
nodal disease. One patient underwent neoadjuvant chemo-
therapy prior to CGD and OS for 40 months, and another un-
derwent adjuvant radiotherapy and had disease-free survival
of 13 months. In our series, a patient with pelvic nodal
involvement survived for 51 months after pelvic lymphade-
nectomy without any adjuvant therapy.
Thus, in these patients with pelvic nodal disease, a more
thorough metastatic workup including positron emission
tomography (PET) would be helpful in avoiding unnecessary
surgery. It was shown in a series by Aoyagi et al24 that
although PET was useful in excluding distant metastases in
patients with EMPD, it could not reliably detect nodal me-
tastases <10 mm in size.
If the disease is confirmed to be locoregional, based on
the favorable survival rates from the aforementioned study
and our series, these patients may benefit from neo-
adjuvant or adjuvant chemoradiotherapy.
Table 3 Comparison of the series of patients with genital extramammary Paget disease for nodal dissection, regional nodal metastases, and survival.
Study No. of patients who underwent
lymphadenectomy according
to depth of invasion of
primary lesion
Sentinel lymph
node positivity
Groin inguinal nodal
involvement after
inguinal lymphadenectomy
(inclusive of SLN)
Regional recurrence
patterns
Survival analysis of
patients with
nodal mets
Adjuvant therapy
Tsutsumida et al11
Japan n Z 36
Carcinoma in situ 0/16
Microinvasion to papillary
dermis
0/6
IRD 4/6
IST 6/6
Not done 3/4 IRD patients positive,
(no. of nodes not described)
6/6 IST patients positive
(no. of nodes not described)
Not described 5-y cumulative survival
rates 33.3% of 6 patients
in the IRD group.(range:
19e63 mo)
All 3 patients with nodal
mets died before 5 y
5-y cumulative survival
rates 0% in the IST group
(range 6e34 mo)
No mention of
adjuvant therapy
Ito et al12 Japan
n Z 36
Intraepidermal 0/18
Microdermal invasion 0/9
Deep invasion into dermis 5/8
4/12 depth of
invasion of
primary lesion
not specified
2 patients had systemic metes
3/3 patients positive (no. of
nodes not described)
2/30 6% local
recurrence
24-66 mo
5-y survival of patients
with nodal mets 20%
3 received RT
4 received
chemotherapy
Hatta et al13
Japan n Z 13
Intra epidermal invasion 0/4
Microdermal invasion 0/5
Dermal invasion 3/4
Not done
1/5
3/4
No inguinal dissection done
in the patient with
microdermal invasion due
to age.
3/3 patients with dermal
invasion had positive
inguinal nodes
(1) 1/10 nodes,
(2) 9/9 nodes,
(3) 1/8 nodes
Recur at 3 mo
Systemic mets
<12 mo
18 mo alive with disease
(1) 10 mo died of disease
(2) 12 mo alive with
disease
(3) 3 mo no evidence
of disease
No mention of
adjuvant therapy
Zhang et al15
China n Z 25
Intradermal 0/12,
Dermal invasion 1/13
Not done 1 patient positive (no. of
nodes not described)
7/24 (29.2%), {2/7
nodal mets} (all
surgically treated)
loco-regional
recurrence
Median 21 mo
Died 26 mo later with
systemic metastases
Not described
for the patient
with nodal mets
Chan et al16
Hong Kong
n Z 48
Carcinoma in situ 1/39
Dermal invasion
6/9
Not done 1 patient had systemic mets
6/7 patients positive (no. of
nodes not described)
Overall recurrence
14.6%
Median 24 mo
No mention about long
term survival for all
patients
No mention of
adjuvant therapy
Hegarty et al17
USA n Z 20
Intraepidermal 1/8
Dermal invasion 5/10
Unknown 2/2
Not done 5/5 patients positive (no. of
nodes not described)
Not specified Median survival invasive
disease 14.5 mo
One disease free 13 mo
Two alive with disease
7 and 40 mo
Two died 16 and 31 mo
2  neoadjuvant
chemo 3  adjuvant
chemo
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Management of inguinal nodal metastases 45Some centers have explored the use of adjuvant therapy
such as chemotherapy or radiotherapy postsurgery. No
effective chemotherapy regimen for locally advanced or
metastatic EMPD has been established because of the lack
of consistent clinical response to any prescribed regimen.3
In a case described by Takahagi et al,25 a combination of
paclitaxel and trastuzumab was used in a patient with
locally recurring skin lesions after initial excision with
dramatic clinical response. However, the patient developed
cerebral metastases 6 months after successful resolution of
the skin lesions.25 Although encouraging, a consistently
effective chemotherapy regimen still needs to be isolated
to achieve long-term benefit.
Radiotherapy has been used in the treatment of perianal
EMPD with no local recurrence after adjuvant radiotherapy
(n Z 0/3) compared to 25% local recurrence with surgery
alone in nine patients.4 In our case series, none of our pa-
tients received adjuvant radiotherapy postsurgery, and
there were no patients in whom locoregional recurrence of
disease developed.
In the management of early EMPD with no clinical evi-
dence of nodal metastases, some authors have suggested
the use of sentinel lymph node (SLN) biopsy.13 In that study,
three of 12 patients with no clinical evidence of nodal
involvement were found to have a positive SLN biopsy result
and subsequently underwent inguinal lymphadenectomy.
This indicates that a significant proportion of patients with
no initial clinical evidence of nodal metastases might har-
bor clinically silent micrometastases. Notably, one patient
was found to have extensive nodal involvement in all nine
lymph nodes, and subsequent radiological investigations
revealed bony metastases. The patient was alive 12 months
after surgery.
Patients with EMPD might present with palpable inguinal
nodes for a variety of reasons. Enlargement of regional
nodes are caused by previous or concurrent infections and
inflammation leading to reactive lymphadenopathy or true
nodal metastases caused by regional spread of tumor; thus,
accurate clinical diagnosis is difficult. Zhang et al15 re-
ported six cases of palpable inguinal nodes, of which only
one patient had metastatic disease. Thus, confirmation of
nodal disease with SLN biopsy or imaging can potentially
avoid unnecessary nodal dissections.
In a study discussing SLN biopsy in patients with EMPD by
Nakamura et al,18 10 of 27 patients with genital EMPD were
found to have positive SLN biopsy results. There was no
postoperative morbidity from the SLN biopsy. Of those 10
patients, seven underwent inguinal nodal dissection. Signif-
icantly, four of the seven of those who underwent nodal
dissection were disease free during the follow-up period
(17e37 months). There was only one patient of 17 with
negative SLN in whom inguinal nodal disease eventually
developed. Importantly, this study included seven patients
with palpable inguinal lymph nodes and no correlation was
found between clinically palpable nodes and pathological
involvement, three had negative SLN biopsy results, and four
had a positive SLN biopsy result. It was thus advocated by
the authors that SLN biopsy should be applied in all cases in
view of the low morbidity of the procedure and the predic-
tive value of SLN biopsy in inguinal nodal dissection.
In conclusion, primary genital EMPD with nodal metas-
tases historically bears a poor prognosis. However,
46 Y.X. Koh et al.aggressive lymphadenectomy in selected cases can provide
a long-term survival benefit. The use of Cloquet node in the
prediction of pelvic nodal disease should be considered.
Based on the literature review, SLN can potentially di-
agnose occult metastases in otherwise nonenlarged nodes.
Further studies to determine the efficacy of SLN in the
management of EMPD are needed.References
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